Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.
Actively Recruiting
Researchers are evaluating enlicitide decanoate, an oral PCSK9 inhibitor, for treating children and adolescents aged 6 to 17 years with heterozygous familial hypercholesterolemia HeFH who have high levels of low-density lipoprotein cholesterol LDL-C in their blood. The study aims to assess the safety, tolerability, and how the body processes enlicitide, as well as its ability to lower cholesterol compared to a placebo. This is a combined Phase 23 treatment trial sponsored by Merck Sharp & Dohme LLC. Participants receive enlicitide decanoate orally once daily with dosage based on age. The study includes an initial short 2-week treatment period Part A, followed by a 24-week period Part B where participants receive either enlicitide or a placebo. Those completing either part may join an open-label extension, receiving enlicitide daily for up to 3 years. The study uses a randomized, parallel design with quadruple masking. Throughout the study, participants undergo blood tests to measure drug concentration and cholesterol levels, including LDL-C and other lipid markers. Safety is closely monitored by tracking adverse events and treatment discontinuations over approximately 3.5 years. Researchers also assess changes in carotid artery thickness. Visits occur regularly during treatment phases, with long-term follow-up in the extension phase, allowing evaluation of both short- and long-term effects of enlicitide in this pediatric population.
Actively Recruiting
Researchers are evaluating how well elritercept works to improve anemia in adults with myelofibrosis MF who are already taking ruxolitinib. The study compares elritercept to a placebo and aims to learn if elritercept reduces tiredness, improves symptoms related to MF, helps participants be more active, and impacts the bone marrow and spleen. The safety of elritercept is also being assessed over a long period. This is a Phase 3, double-blind, randomized trial sponsored by Takeda. Participants will receive either elritercept or a matching placebo as a subcutaneous injection every 4 weeks for approximately 36 weeks during the double-blinded treatment period. Elritercept starts at a dose of 3.75 mgkg, with a possible increase to 5.0 mgkg from the third cycle based on response and safety. After this period, those on placebo may switch to elritercept during an extended open-label phase where dosing adjustments are also possible. During the study, participants will be monitored regularly with assessments including blood transfusion independence, fatigue levels, symptom scores, spleen size by imaging, and development of antibodies to the study drug. Researchers will track safety and overall survival for up to seven years. Participants can expect visits every 4 weeks during treatment, and the study includes long-term follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are studying finerenone to find a better long-term treatment for children and young adults with heart failure and left ventricular systolic dysfunction LVSD, a condition where the hearts left side is weak and cannot pump blood well. The study aims to understand how safe finerenone is and how well it works when added to standard heart failure treatments in participants from newborns up to 18 years old. Participants will receive finerenone treatment for up to 9 months while continuing their usual heart failure care. The study includes children and young adults who joined an earlier finerenone trial and newly enrolled newborns under 6 months old with LVSD. Participants will attend at least six visits during the treatment period, where various health checks and tests will be done. During the study visits, researchers will measure vital signs, take blood samples, perform heart tests like electrocardiograms and echocardiograms, and ask about medication use and any medical problems. Parents or guardians of newborns and infants will provide feedback on how acceptable the study drug formulation is. After finishing treatment, participants will have a follow-up health check about one month later. The study will monitor safety by tracking medical problems and changes in potassium levels, blood pressure, and kidney function.
Actively Recruiting
Researchers are studying children with heart failure caused by left ventricular systolic dysfunction LVSD, a condition where the heart cannot pump enough blood. The goal is to see if the drug finerenone, which blocks a protein related to inflammation and scarring, can help the heart pump better compared to a placebo. This is the first study to test finerenone specifically in children with heart failure and LVSD, focusing on safety and effects on heart stress markers. Participants aged 6 months to under 18 years will be randomly assigned to receive either finerenone or a placebo for about three months, alongside their regular heart failure treatments. After this period, those who qualify may join an additional nine-month open-label phase where all receive finerenone. Those who do not join the extension will have a follow-up visit one month after finishing treatment. During the study, participants will visit the clinic at least three times for physical exams, heart tests including ECG and echocardiogram, blood tests, and measurements like blood pressure and heart rate. Researchers will track changes in a heart stress protein called NT-proBNP, monitor safety by recording any adverse events, and measure other heart function markers. The total study duration can be up to about a year including the extension and follow-up.
Actively Recruiting
Researchers are evaluating the effects of a synbiotic containing Lactobacillus acidophilus and agave inulin on cognitive function in adults with obesity and mild cognitive impairment. This randomized crossover trial involves 40 participants aged 30 to 40 years who have had obesity for over 10 years and mild cognitive decline. The study aims to explore how the synbiotic might influence cognition and related biological markers through the gut-brain axis. Participants will receive a daily dose of 2 grams of Lactobacillus acidophilus combined with 7 grams of agave inulin mixed with a powder of almond, cinnamon, vanilla, and oats dissolved in water. The intervention lasts 12 weeks, after which participants will switch to a control preparation for another 12 weeks. This crossover design allows each participant to experience both the synbiotic and control interventions sequentially. Throughout the trial, cognitive function will be assessed at the start, week 12, and week 26 using the Montreal Cognitive Assessment MoCA, Mini-Mental State Examination MMSE, and Memory Alteration Test MT. In addition, researchers will measure fecal butyrate, Lactobacillus acidophilus levels, serum inflammatory cytokines, and brain-derived neurotrophic factor to understand potential mechanisms. Participation involves regular assessments and monitoring over 26 weeks to evaluate changes in cognition and related biological markers.
Actively Recruiting
Diffuse large B-cell lymphoma DLBCL is a fast-growing and uncommon cancer affecting certain immune cells, and it is the most common type of non-Hodgkin lymphoma. Follicular lymphoma FL is a slower-growing form of non-Hodgkin lymphoma. This research aims to evaluate how well the investigational drug epcoritamab works in adults with advanced DLBCL and FL in real-world medical settings. Participants will receive epcoritamab as prescribed by their doctors following local country guidelines. The study will include about 700 adults treated across roughly 80 sites in 12 to 20 countries. Treatment is given as subcutaneous injections, and the study observes participants over up to three years to gather effectiveness information. During the study, participants will continue their regular hospital or clinic visits as part of their usual care, without extra procedures or visits added by the trial. Researchers will monitor the percentage of participants who achieve an overall response to the treatment over approximately three years. The study is observational, meaning it follows patients receiving epcoritamab under normal clinical practice without altering their care.